Bailard Inc. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,294 shares of the company's stock after purchasing an additional 6,087 shares during the quarter. Bailard Inc.'s holdings in Johnson & Johnson were worth $23,432,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $38,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
JNJ stock traded up $0.67 during mid-day trading on Friday, reaching $163.65. The company's stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,146,242. The stock has a market cap of $393.75 billion, a PE ratio of 17.50, a P/E/G ratio of 2.21 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company's 50 day moving average is $154.10 and its two-hundred day moving average is $154.84.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 EPS. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.
Wall Street Analyst Weigh In
Several equities research analysts have commented on JNJ shares. Guggenheim upped their price target on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a report on Thursday. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $174.11.
Read Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
